Dr. Marcus A. Urey, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
200 W Arbor Dr
San Diego, CA 92103
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Geffen School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 351
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of California, Geffen School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
CA license A148944 (first issued 2017; current) -
Cardiovascular Disease Physician
CA license A148944 (first issued 2017; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
- Eisenhower Medical Center Rancho Mirage, CA
Medical groups
- Regents of the University of California (2,089 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 351
- Services billed
- 1,233
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 217 | 72 |
| Established patient office or other outpatient visit, 30-39 minutes | 204 | 151 |
| Established patient office or other outpatient visit, 40-54 minutes | 119 | 99 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 83 | 34 |
| Critical care, first 30-74 minutes | 62 | 12 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 49 | 46 |
| New patient office or other outpatient visit, 60-74 minutes | 48 | 48 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 47 | 46 |
| Hospital discharge day management, 30 minutes or less | 39 | 37 |
| Evaluation of lower heart chamber assist device | 29 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vyndamax (tafamidis) | 353 |
| Rosuvastatin Calcium Other prescribers in San Diego, CA | 337 |
| Jardiance (empagliflozin) Other prescribers in San Diego, CA | 336 |
| Spironolactone Other prescribers in San Diego, CA | 197 |
| Sirolimus | 193 |
| Eliquis (apixaban) Other prescribers in San Diego, CA | 173 |
| Bumetanide Other prescribers in San Diego, CA | 168 |
| Famotidine Other prescribers in San Diego, CA | 151 |
| Losartan Potassium Other prescribers in San Diego, CA | 143 |
| Entresto (sacubitril/valsartan) Other prescribers in San Diego, CA | 139 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 53 payments worth $76,025 in total to this clinician.
| Bridgebio Pharma, Inc. | $44,005 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $20,729 |
| Alnylam Pharmaceuticals Inc. | $9,983 |
| Abiomed | $840 |
| Abbott Laboratories | $400 |
| Edwards Lifesciences Corporation | $49.27 |
| Scpharmaceuticals Inc. | $19.07 |
| Compensation for services other than consulting (speaking, faculty) | $49,630 |
|---|---|
| Consulting Fee | $19,262 |
| Travel and Lodging | $5,818 |
| Food and Beverage | $1,315 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bridgebio Pharma, Inc. May 27, 2025 | Consulting Fee Attruby · Cardiomyopathy | $8,845 |
| AstraZeneca Pharmaceuticals LP Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $4,300 |
| Bridgebio Pharma, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $4,190 |
| Bridgebio Pharma, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $4,190 |
| AstraZeneca Pharmaceuticals LP Apr 2, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $3,759 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,750 |
| Alnylam Pharmaceuticals Inc. Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $2,820 |
| Bridgebio Pharma, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
All 36 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Bridgebio Pharma, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $4,190 |
| Bridgebio Pharma, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Nov 20, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Las Vegas, NV | $162 |
| Bridgebio Pharma, Inc. Nov 20, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Las Vegas, NV | $76.00 |
| Bridgebio Pharma, Inc. Nov 11, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Las Vegas, NV · in-kind | $357 |
| Bridgebio Pharma, Inc. Nov 11, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Las Vegas, NV · in-kind | $172 |
| AstraZeneca Pharmaceuticals LP Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Oct 9, 2025 | Travel and Lodging WAINUA · Cardiovascular and Metabolism · travel to Kahuku, HI · in-kind Company’s descriptionSpeaker Expenses | $274 |
| Bridgebio Pharma, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $4,190 |
| Bridgebio Pharma, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| AstraZeneca Pharmaceuticals LP Oct 1, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $2,685 |
| Bridgebio Pharma, Inc. Sep 9, 2025 | Consulting Fee Attruby · Cardiomyopathy | $1,862 |
| Bridgebio Pharma, Inc. Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,397 |
| AstraZeneca Pharmaceuticals LP Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $100 |
| Bridgebio Pharma, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,750 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Los Angeles, CA | $260 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Los Angeles, CA | $164 |
| Bridgebio Pharma, Inc. May 27, 2025 | Consulting Fee Attruby · Cardiomyopathy | $8,845 |
| Bridgebio Pharma, Inc. May 27, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $90.88 |
| Alnylam Pharmaceuticals Inc. Apr 24, 2025 | Travel and Lodging travel to San Diego, CA | $1,934 |
| Alnylam Pharmaceuticals Inc. Apr 24, 2025 | Travel and Lodging travel to San Diego, CA | $962 |
| AstraZeneca Pharmaceuticals LP Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Apr 2, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $3,759 |
| AstraZeneca Pharmaceuticals LP Mar 29, 2025 | Travel and Lodging WAINUA · Cardiovascular and Metabolism · travel to Chicago, IL · in-kind Company’s descriptionSpeaker Expenses | $699 |
| AstraZeneca Pharmaceuticals LP Mar 29, 2025 | Travel and Lodging WAINUA · Cardiovascular and Metabolism · travel to Chicago, IL · in-kind Company’s descriptionSpeaker Expenses | $655 |
| AstraZeneca Pharmaceuticals LP Mar 29, 2025 | Travel and Lodging WAINUA · Cardiovascular and Metabolism · travel to Chicago, IL · in-kind Company’s descriptionSpeaker Expenses | $105 |
| Alnylam Pharmaceuticals Inc. Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $2,820 |
| AstraZeneca Pharmaceuticals LP Feb 2, 2025 | Consulting Fee | $1,611 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $2,150 |
| Abiomed Jan 7, 2025 | Consulting Fee | $500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $373,364 in research payments for these studies, mostly to the institutions running them.
- CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. · Completed · NCT04136171 - A phase 3,radomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of amyloid depleter ALXN2220 in adult participants wiith transthyretin amyloid cardiomyopathy ATTR CM
Alexion Pharmaceuticals, Inc. - An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. · Enrolling by invitation · NCT05667493 - A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic C…
E.r. Squibb & Sons, L.l.c. - A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outfl…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.